Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 16:00:00 2024-06-10 EDT			5-day change	1st Jan Change
25.59 ^USD	+0.08%		-.--%	+58.65%

06-11	Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion	DJ
06-11	Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes	CI

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

January 03, 2023 at 04:02 pm

Deciphera Pharmaceuticals, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year 2022. For the quarter, the company expects revenue to be approximately $36 million.

For the full year 2022, The company expects revenue to be approximately $134 million.

Latest news about Deciphera Pharmaceuticals, Inc.

Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion	06-11	DJ
Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes	06-11	CI
Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion	06-11	MT
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index	06-10	CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index	06-10	CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index	06-10	CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index	06-10	CI
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Biotechnology Index	06-09	CI
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor At the 2024 Asco Annual Meeting and Online Publication in the Lancet	06-03	CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
North American Morning Briefing : Traders Wait for -2-	05-01	DJ
Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	04-30	MT
Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	04-30	MT
JMP Downgrades Deciphera Pharmaceuticals to Market Perform	04-30	MT
North American Morning Briefing : More Earnings -2-	04-30	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	04-30	RE
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	04-29	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	04-29	MT
Top Midday Gainers	04-29	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	04-29	MT
Sector Update: Health Care	04-29	MT
JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	04-29	MT
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical	04-29	MT
Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	04-29	MT
Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma	04-29	DJ

Chart Deciphera Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DECIPHERA PHARMACEUTICALS, INC.	+58.65%	2.21B
VERTEX PHARMACEUTICALS INCORPORATED	+16.43%	122B
REGENERON PHARMACEUTICALS, INC.	+18.97%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.40%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-20.10%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+59.69%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.30%	14.1B

Bio Therapeutic Drugs